Global Extramammary Paget Disease Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Extramammary Paget Disease Market Segmentation By Type (Primary and Secondary), Diagnosis (Needle Biopsy, Ultrasound, Colonoscopy, Cervical Smear, and Mammography), Treatment (Surgery, Radiation Therapy, Aminolevulinic Acid Based Photodynamic Therapy, Laser Ablation, Chemotherapy Drug and Others), Route of Administration (Oral, Topical, Parenteral, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) - Industry Trends and Forecast to 2032

Extramammary Paget Disease Market Size

• The global Extramammary Paget Disease market size was valued at USD 238.66 million in 2024 and is expected to reach USD 360.75 million by 2032, at a CAGR of 5.30% during the forecast period
• The market growth is largely fueled by the growing adoption and technological progress in dermatological diagnostics and targeted cancer therapies, leading to improved early detection and personalized treatment of rare skin cancers such as Extramammary Paget Disease (EMPD)
• Furthermore, rising consumer and clinical demand for accurate, minimally invasive, and effective treatment options is establishing novel topical agents, immunotherapies, and surgical innovations as the standard of care in managing EMPD. These converging factors are accelerating the uptake of Extramammary Paget Disease solutions, thereby significantly boosting the industry's growth

Extramammary Paget Disease Market Analysis

• Extramammary Paget Disease (EMPD) is a rare cutaneous malignancy primarily affecting apocrine gland-bearing areas, most commonly the vulva, scrotum, perianal region, and axilla.
• The market for EMPD treatment is evolving with improved diagnostic techniques and targeted therapies
• North America dominated the Extramammary Paget Disease market with the largest revenue share of 40.7% in 2024, driven by advanced healthcare infrastructure, early disease recognition, and the increasing adoption of immunotherapy and surgical innovations. The presence of leading research institutes, strong reimbursement policies, and a focus on rare cancer research contribute to the region's leadership
• Asia-Pacific is expected to be the fastest-growing region in the Extramammary Paget Disease market during the forecast period, with a projected CAGR of 24.1% from 2025 to 2032. Factors driving this growth include rising awareness of skin diseases, increasing healthcare spending, and improved access to dermatological and oncological services in countries such as Japan, China, and South Korea
• The primary segment dominated the Extramammary Paget Disease with the largest revenue share of 68.3% in 2024, primarily due to its higher incidence rate in aging populations and greater clinical detection

Report Scope and Extramammary Paget Disease Market Segmentation      

Extramammary Paget Disease Market Trends

“Advancements in Targeted Therapies and Diagnostic Innovations Driving Market Growth”

• A key trend in the global Extramammary Paget Disease (EMPD) market is the increasing focus on early diagnosis and precision medicine approaches. With EMPD being a rare and often misdiagnosed malignancy, advancements in dermatopathology, immunohistochemistry, and molecular diagnostics are significantly improving detection rates and enabling more accurate treatment decisions

  • For instance, the use of HER2/neu testing has emerged as a critical tool in identifying patients who may benefit from targeted therapies, particularly trastuzumab-based regimens. Studies have shown HER2 positivity in a subset of EMPD patients, paving the way for precision oncology in this rare cancer segment

• Surgical interventions remain the cornerstone of treatment, with Mohs micrographic surgery leading as the preferred method due to its ability to remove cancerous tissues while preserving healthy surrounding tissue. This technique is associated with lower recurrence rates, especially in high-risk anatomical areas like the vulva or perianal region
• The rise in topical chemotherapy agents such as imiquimod and 5-fluorouracil, particularly for patients with in-situ EMPD or those unfit for surgery, is expanding non-invasive treatment options. These treatments offer acceptable local control while minimizing systemic side effects and cosmetic damage
• Moreover, the market is experiencing increased clinical research activity focused on immunotherapies and checkpoint inhibitors, especially for metastatic or recurrent EMPD. Agents targeting the PD-1/PD-L1 pathway are under evaluation, driven by the tumor’s immune microenvironment characteristics
• As awareness grows among dermatologists and oncologists about EMPD's distinctive clinical presentation and management challenges, global collaborations and rare cancer registries are playing an important role in accelerating research, improving epidemiological understanding, and encouraging orphan drug development
• The demand for specialized diagnostic and treatment pathways for EMPD is expected to surge, supported by expanding access to cancer care, increased investment in rare disease R&D, and the emergence of multidisciplinary treatment frameworks in tertiary care centers worldwide

Extramammary Paget Disease Market Dynamics

Driver

“Growing Need Due to Rising Awareness and Early Diagnosis Initiatives”

• The increasing awareness surrounding rare skin malignancies and the importance of early diagnosis is a major driver for the growing demand in the Extramammary Paget Disease (EMPD) market

  • For instance, in April 2024, rare disease awareness campaigns in North America and Europe emphasized early dermatological assessments and genetic screenings, leading to timely detection and better prognosis in EMPD patients. These initiatives are expected to significantly boost the Extramammary Paget Disease industry growth over the forecast period

• As healthcare professionals and patients become more knowledgeable about rare oncological conditions, there is a growing demand for accurate diagnostic tools, targeted therapies, and multidisciplinary care approaches to treat EMPD effectively
• Furthermore, the adoption of advanced molecular diagnostic techniques and immunohistochemical testing is becoming a core component of EMPD detection, driving the demand for more sophisticated and specialized pathology services
• The increasing availability of specialized cancer centers and rare-disease-focused clinics, coupled with growing investments in precision oncology, are enhancing treatment outcomes and expanding access to care. These developments are making Extramammary Paget Disease management more effective and accessible across both developed and emerging markets

Restraint/Challenge

“Limited Treatment Options and High Misdiagnosis Rate”

• The limited availability of FDA-approved therapies and a high rate of misdiagnosis continue to pose significant challenges in the EMPD market. EMPD often mimics benign dermatological conditions like eczema or dermatitis, leading to delays in diagnosis and treatment

  • For instance, studies published in 2023 highlighted that over 40% of EMPD cases are initially misdiagnosed, contributing to disease progression and poorer outcomes

• Developing effective EMPD therapies is also hampered by the rarity of the disease, making it difficult to conduct large-scale clinical trials or attract substantial pharmaceutical investment
• In addition, the high cost of targeted therapies and the need for complex surgical or radiotherapy interventions can be prohibitive, particularly in low-income and underserved regions. Access to advanced immunotherapies or reconstructive surgery is often limited to urban centers or high-resource settings
• Overcoming these challenges will require a concerted effort in physician education, patient outreach, and rare disease funding. Increased clinical research, cross-border collaborations, and the inclusion of EMPD in rare cancer registries are essential steps toward accelerating therapeutic innovation and improving patient outcomes

Extramammary Paget Disease Market Scope

The market is segmented on the basis of type, diagnosis, treatment, route of administration, end-users, and distribution channel.

• By Type

On the basis of type, the Extramammary Paget Disease market is segmented into primary and secondary. The primary segment dominated the market with the largest revenue share of 68.3% in 2024, primarily due to its higher incidence rate in aging populations and greater clinical detection.

The secondary segment is projected to register the fastest CAGR of 7.9% from 2025 to 2032, driven by rising awareness of underlying malignancy screenings and advances in diagnostic pathways.

• By Diagnosis

On the basis of diagnosis, the market is segmented into needle biopsy, ultrasound, colonoscopy, cervical smear, mammography, and others. The needle biopsy segment accounted for the highest market share of 36.7% in 2024, being the gold standard for histological confirmation of EMPD.

The colonoscopy segment is expected to grow at the highest CAGR of 8.2% over the forecast period, particularly in detecting gastrointestinal malignancies linked to secondary EMPD.

• By Treatment

On the basis of treatment, the market is segmented into surgery, radiation therapy, aminolevulinic acid-based photodynamic therapy, laser ablation, chemotherapy drugs, and others. Surgery led the market with a dominant share of 41.5% in 2024, due to its high success rate, especially in primary EMPD cases.

The photodynamic therapy (PDT) segment is forecasted to grow at the highest CAGR of 9.1% from 2025 to 2032, owing to increased adoption in early-stage and non-invasive cases due to fewer side effects.

• By Route of Administration

On the basis of route of administration, the market is segmented into oral, topical, parenteral, and others. The topical segment held the largest share of 38.9% in 2024, driven by the increasing use of non-invasive treatment options like imiquimod and fluorouracil for early disease stages.

The parenteral segment is expected to grow at a fastest CAGR of 7.4% over the forecast period, particularly in advanced EMPD requiring systemic therapies.

• By End-Users

On the basis of end-users, the market is segmented into hospitals, specialty clinics, homecare, and others. Hospitals dominated with a market share of 52.1% in 2024, attributed to the availability of surgical facilities and multidisciplinary cancer care units.

Homecare is projected to expand at the highest CAGR of 8.8% during the forecast period, due to increasing use of topical therapies and home-based patient support programs.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Hospital pharmacies accounted for the largest revenue share of 47.6% in 2024, owing to their central role in dispensing post-surgical medications and chemotherapy agents.

Online pharmacies are expected to grow at the fastest CAGR of 9.4% from 2025 to 2032, driven by rising eHealth adoption and the convenience of medication access for chronic skin conditions.

Extramammary Paget Disease Market Regional Analysis

• North America dominated the Extramammary Paget Disease market with the largest revenue share of 40.7% in 2024, attributed to the increasing awareness of rare skin cancers and well-established diagnostic infrastructure
• Strong research funding, early adoption of advanced diagnostic techniques such as immunohistochemistry and molecular testing, and the presence of key biopharmaceutical players are fueling regional growth
• The rising number of dermatology-focused specialty clinics and growing healthcare expenditures are supporting earlier diagnosis and personalized treatment regimens for EMPD

U.S. Extramammary Paget Disease Market Insight

The U.S. Extramammary Paget Disease market accounted for 81% of North America's Extramammary Paget Disease market in 2024, equivalent to 33% of the global market share. Growth is driven by the country's strong clinical research pipeline, favorable reimbursement environment, and greater access to targeted therapies and surgical interventions. In addition, increasing awareness among healthcare professionals regarding rare dermatologic malignancies is improving diagnostic accuracy and boosting treatment uptake.

Europe Extramammary Paget Disease Market Insight

The Europe Extramammary Paget Disease market is projected to expand at a substantial CAGR through 2032, driven by increasing geriatric populations, national rare disease strategies, and improved access to specialist care. Countries like Germany, France, and the U.K. are key contributors due to their focus on oncologic dermatology, clinical trial activity, and well-organized referral systems for rare diseases. extramammary paget disease market cases are increasingly managed through multidisciplinary oncology centers, improving prognosis and outcomes.

U.K. Extramammary Paget Disease Market Insight

The U.K. Extramammary Paget Disease market is expected to grow at a noteworthy CAGR during the forecast period, bolstered by NHS-led rare disease initiatives and growing demand for precise pathology services. A rising emphasis on early cancer screening, government-backed research programs, and strong collaboration between academic and healthcare institutions are contributing to market development.

Germany Extramammary Paget Disease Market Insight

The Germany Extramammary Paget Disease market is set to expand at a significant CAGR, supported by a robust healthcare system, strong pathology networks, and an emphasis on advanced imaging and diagnostics. The country’s high standards for medical device and pharmaceutical innovation are facilitating early adoption of new treatment modalities, including immunotherapy and targeted therapies.

Asia-Pacific Extramammary Paget Disease Market Insight

The Asia-Pacific Extramammary Paget Disease market is poised to grow at the fastest CAGR of 24.1% from 2025 to 2032, due to increased healthcare infrastructure, government investments in cancer care, and expanding medical awareness in countries such as China, Japan, and India. Rising medical tourism and the presence of emerging biotechnology companies are expected to further boost the region's share in the global EMPD market. Educational campaigns and increasing skin cancer awareness are improving patient outcomes by encouraging early specialist referrals.

Japan Extramammary Paget Disease Market Insight

The Japan Extramammary Paget Disease market is gaining momentum, driven by the country’s aging population, tech-savvy healthcare system, and prioritization of rare cancer management through precision medicine. Rising collaborations between dermatology clinics and academic hospitals, alongside a growing emphasis on minimally invasive surgical techniques, are enhancing the treatment landscape.

China Extramammary Paget Disease Market Insight

China Extramammary Paget Disease market accounted for the largest revenue share in the Asia-Pacific EMPD market in 2024, driven by urbanization, access to specialized oncology care, and government investments in rare disease diagnosis. The country is witnessing growing adoption of molecular diagnostics, and partnerships with global pharmaceutical companies are facilitating early market entry of advanced therapies.

Extramammary Paget Disease Market Share

The Extramammary Paget Disease industry is primarily led by well-established companies, including:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Viatris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson Services, Inc. (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH (Germany)
• Dr. Reddy’s Laboratories Ltd. (India)
• Gilead Sciences, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Lilly (U.S.)
• AbbVie Inc. (U.S.)
• Lupin (India)

Latest Developments in Global Extramammary Paget Disease Market

• In July 2024, the Mayo Clinic reported that a multidisciplinary surgical approach using modified Mohs micrographic surgery significantly improved 3‑year recurrence‑free survival—93.3% vs. 65.9% for conventional wide local excision—in female genital EMPD
• In February 2024 study has identified FOXM1 as a promising therapeutic target in EMPD. Elevated FOXM1 expression correlated with disease progression, and inhibiting it with thiostrepton reduced tumor cell viability in vitro

SKU-68640